Old Web
English
Sign In
Acemap
>
authorDetail
>
Mei Wu
Mei Wu
Genentech
Medicine
Internal medicine
Oncology
relapsed refractory
Chronic lymphocytic leukemia
5
Papers
3
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Healthcare Resource Utilization and Costs of Patients with Relapsed/Refractory Follicular Lymphoma Receiving 3 or More Lines of Therapy
2021
Blood
Matthew J. Matasar
Sheila Shapouri
Jamie T. Ta
Tu My To
Mei Wu
Rongrong Wang
Show All
Source
Cite
Save
Citations (0)
Treatment Patterns and Outcomes Among Patients with Relapsed/Refractory Follicular Lymphoma Treated in Routine Clinical Practice in the US with Three or More Lines of Therapy
2021
Blood
Jamie T. Ta
Stella Arndorfer
Cristina Julian
Mei Wu
Dominic Lai
Sheila Shapouri
Show All
Source
Cite
Save
Citations (0)
Impact of premature venetoclax (Ven) discontinuation/interruption on outcomes in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): Phase III MURANO study results.
2020
Journal of Clinical Oncology
Anthony R. Mato
Jeff P. Sharman
Juliana Biondo
Mei Wu
Yong Mun
Su Young Kim
Kathryn Humphrey
Michelle Boyer
Qian Zhu
John F. Seymour
Show All
Source
Cite
Save
Citations (2)
1